Company intelligence / Profile preview

Emtora Biosciences

Ownership: Private
Development stage: Phase 3

Overview

Completed Phase 1 safety and dose escalation study in low grade prostate cancer patients in 2019. Phase 2 studies in Familial Adenomatous Polyposis (FAP) and non-muscle invasive bladder cancer (NMIBC) are underway. Compelling six-month data from Phase 2 study of eRapa in FAP were presented at Digestive Disease Week in April 2024, and 12-month data were presented at InSIGHT, Barcelona in June 2024. A registrational Phase 3 study is expected to begin recruitment soon.

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecules (rapamycin formulation)
Industry: Biotech

Drug pipeline

1 asset

eRapa

Phase 3

Indications: Familial Adenomatous Polyposis, Non-muscle invasive bladder cancer, Low grade prostate cancer

Partnerships

Biodexa Pharmaceuticals PLC (exclusive worldwide license agreement for eRapa™)

Beyond the preview

Go deeper on Emtora Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Emtora Biosciences.

Explore the full profile